| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 06/06/2001 | EP1104754A1 Novel sulfonyl derivatives |
| 06/06/2001 | EP1104674A1 O,o'-dihydroxy azo dyes as medicinal components with TPO-agonistic or -synergetic activity |
| 06/06/2001 | EP1104465A1 14400 receptor, a g-protein coupled receptor |
| 06/06/2001 | EP1104421A1 3-(4-amino-5-ethylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1h-pyrazolo 3,4-b]pyridine |
| 06/06/2001 | EP1104323A1 Apparatus and method of preparation of stable, long term thrombin from plasma and thrombin formed thereby |
| 06/06/2001 | EP1104309A2 Protected one-vial formulation for nucleic acid molecules, methods of making the same by in-line mixing, and related products and methods |
| 06/06/2001 | EP1104273A1 Indwelling heat exchange catheter and method of using same |
| 06/06/2001 | CN1298389A Cyclic amino compounds |
| 06/05/2001 | US6242644 N-(4-carbamimidoyl-phenyl)-glycine derivatives |
| 06/05/2001 | US6242637 Substituted heterocylic compounds, method of preparing them and pharmaceutical compositions in which they are present |
| 06/05/2001 | US6242601 Heterocyclic sulfamides |
| 06/05/2001 | US6242568 Zinc finger protein derivatives and methods therefor |
| 06/05/2001 | US6242479 Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of disease |
| 06/05/2001 | US6242454 Benzamidine derivatives substituted by amino acid and hydroxy acid derivatives and their use as anti-coagulants |
| 06/05/2001 | US6242444 5-(2,3-dihydro-5-(4-methylpiperazin-1-ylsulfonyl)-7-benzofuryl )-1-methyl-3-propyl-6,7-dihydro-1h-pyrazolo(4,3-d)pyrimidin-7-one, for example; treatment of inter alia erectile dysfunction. |
| 06/05/2001 | US6242432 Antihypertensive activity, antihypersensitive activity; treatment of cardiovascular disease |
| 06/05/2001 | US6242422 (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases |
| 06/05/2001 | US6242249 Nucleotide sequences of trigger factor chaperones from staphylococcus; diagnosis; probes; primers; vaccines; bactericides; bacteriostats; antibodies; drug screening |
| 06/05/2001 | US6242218 Dna construct for altering gene expression of endogenous granulocyte-colony stimulating factor in mammalian cell; gene therapy; culture production |
| 06/05/2001 | CA2124937C T-pa substitution variants with improved fibrin-specificity |
| 06/03/2001 | CA2327385A1 Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents |
| 06/03/2001 | CA2327256A1 Heteroaryl phenyl pyrazole compounds as anti-inflammatory/analgesic agents |
| 05/31/2001 | WO2001038495A2 Method for producing a thrombocyte preparation and a thrombocyte preparation |
| 05/31/2001 | WO2001038393A1 Polypeptides derived from vitamin d nuclear receptor, and their uses in particular for screening vitamin d analogues |
| 05/31/2001 | WO2001038361A1 Modified adenovirus fibre and uses |
| 05/31/2001 | WO2001038325A1 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| 05/31/2001 | WO2001038323A1 Pyrazinone thrombin inhibitors |
| 05/31/2001 | WO2001038314A1 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors |
| 05/31/2001 | WO2001038313A1 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p39 kINASE INHIBITORS |
| 05/31/2001 | WO2001038312A1 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p38 KINASE INHIBITORS |
| 05/31/2001 | WO2001038309A1 β-AMINO ACID-, ASPARTIC ACID- AND DIAMINOPROPIONIC-BASED INHIBITORS OF FACTOR Xa |
| 05/31/2001 | WO2001038305A2 Novel il-8 receptor antagonists |
| 05/31/2001 | WO2001037868A1 Assays and therapies for latent viral infection |
| 05/31/2001 | WO2001037857A1 Major intrinsic protein (mip)-like polynucleotides, polypeptides, and antibodies |
| 05/31/2001 | WO2001037823A1 Substituted nitrobenzene derivatives as medicines and other useful uses thereof |
| 05/31/2001 | WO2001037821A1 Cell permeable peptides for inhibition of inflammatory reactions and methods of use |
| 05/31/2001 | WO2001037818A2 Medicament and combination of compatible medicaments |
| 05/31/2001 | WO2001037808A1 Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| 05/31/2001 | WO2000075172A3 Factor viia inhibitors |
| 05/31/2001 | WO2000071140A3 Methods and compositions for modulating immune response and for the treatment of inflammatory disease |
| 05/31/2001 | WO2000061754A3 Human proteins and polynucleotides encoding them |
| 05/31/2001 | WO2000032772A3 Erythropoietic compounds |
| 05/31/2001 | WO1999032454A9 Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors |
| 05/31/2001 | US20010002419 Homogeneous preparation of protein, e.g. leptin, modified at the N-terminal only by an anhydride, e.g. succinic anhydride, ethylenediaminetetraacetic dianhydride; improved solubility; no inflammation at injection sites |
| 05/31/2001 | US20010002398 (6S)- or 10 (6R,S)- tetrahydrofolic acid is crystallized in a polar medium with pH of 3.5 or greater and have a purity 98% |
| 05/31/2001 | CA2706113A1 Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| 05/31/2001 | CA2392576A1 .beta.-amino acid-, aspartic acid- and diaminopropionic-based inhibitors of factor xa |
| 05/31/2001 | CA2392456A1 Assays and therapies for latent viral infection |
| 05/31/2001 | CA2392366A1 Major intrinsic protein (mip)-like polynucleotides, polypeptides, and antibodies |
| 05/31/2001 | CA2392272A1 Modified adenovirus fibre and uses |
| 05/31/2001 | CA2392225A1 Novel il-8 receptor antagonists |
| 05/31/2001 | CA2391943A1 Cell permeable peptides for inhibition of inflammatory reactions and methods of use |
| 05/31/2001 | CA2391012A1 Pyrazinone thrombin inhibitors |
| 05/31/2001 | CA2390923A1 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| 05/31/2001 | CA2388103A1 Medicament and combination of compatible medicaments |
| 05/30/2001 | EP1103553A2 Substituted heterocyclic derivatives |
| 05/30/2001 | EP1103544A2 Piperidine derivatives and antiplatelet agents containing the same |
| 05/30/2001 | EP1102838A2 A method of modulating the efficiency of translation termination and degradation of aberrant mrna involving a surveillance complex comprising human upf1p, eucaryotic release factor 1 and eucaryotic release factor 3 |
| 05/30/2001 | EP1102768A1 Substituted pyrazole derivatives condensed with six-membered heterocyclic rings |
| 05/30/2001 | EP1102767A1 Substituted pyrazole derivatives |
| 05/30/2001 | EP1102766A1 Triazolopyridines for the treatment of thrombosis disorders |
| 05/30/2001 | EP1102761A2 Cyclopentabenzofuran derivatives and their use |
| 05/30/2001 | EP1102746A1 Substituted phenylamidines with antithrombotic action |
| 05/30/2001 | EP1102601A1 Targeting and prolonging association of drugs to the luminal surface of the pulmonary vascular endothelial cells |
| 05/30/2001 | EP1102585A2 USE OF CYCLOPENTABENZOFURAN-DERIVATIVES FOR COMBATING NF-$g(k)B-DEPENDENT DISEASES |
| 05/30/2001 | EP0637306B1 4-imidomethyl-1- [2'-phenyl-2'-oxoethyl]- piperidines as serotonin 5ht 2-antagonists, their preparation and use in therapy |
| 05/30/2001 | EP0621788B1 Hemoregulatory peptides |
| 05/30/2001 | CN1297459A Method for production of polymers from N-vinyl compounds |
| 05/30/2001 | CN1297452A Modified factor VIII |
| 05/30/2001 | CN1297440A Piperidinyl and N-amidinopiperidinyl derivs. |
| 05/30/2001 | CN1297435A Method for producing enantiomer-free N-methyl-N-[(1S)-1-phenyl-2-[(3S)-3-hydroxypyrrolidine-1-y1)ethyl]-2, 2-diphenyl acetamide |
| 05/30/2001 | CN1297351A Intermittent claudication therapeutic drugs comprising pyrroloazepines |
| 05/30/2001 | CN1296829A Quickly thrombus dissolving tablet |
| 05/29/2001 | US6239176 Administering to treat blood disorders like anemia; wound healing, anticarcinogenic and antiproliferative agents; genetic disorders |
| 05/29/2001 | US6239173 Antiinflammatory, antipyretic, analgesic, and antiarthritic agents |
| 05/29/2001 | US6239171 Tocotrienols and tocotrienol-like compounds and methods for their use |
| 05/29/2001 | US6239151 Compounds as inhibitor of tumor necrosis factor alpha release |
| 05/29/2001 | US6239138 Vitronectin receptor antagonist |
| 05/29/2001 | US6239132 Thrombin inhibitors |
| 05/29/2001 | US6239109 Method of promoting erythropoiesis |
| 05/29/2001 | US6239106 Family of protease inhibitors, and other biologic active substances |
| 05/29/2001 | US6239102 Concentrate comprising, as active agent, (3'-desoxy-3-oxo-mebmc)1-(val)2-cyclosporin, stabilizer selected from oleic acid or palmitoyl oleoyl phosphatidyl glycerol or salts thereof, ethanol |
| 05/29/2001 | US6238914 Nucleic acid |
| 05/29/2001 | US6238878 FVlla/TF activity inhibiting compounds |
| 05/29/2001 | US6238665 Anti-edema agent |
| 05/29/2001 | CA2034881C Factor x-laci hybrid protein |
| 05/25/2001 | WO2001036645A2 Serine/threonine kinase and serine protease polypeptides and nucleic acids encoding same |
| 05/25/2001 | WO2001036624A1 High order nucleic acid based structures |
| 05/25/2001 | WO2001036616A2 Acid nucleic construct bearing a system regulating the expression of a gene |
| 05/25/2001 | WO2001036611A1 Process for the production of a reversibly inactive acidified plasmin composition |
| 05/25/2001 | WO2001036610A1 Human enzymes of the metalloprotease family |
| 05/25/2001 | WO2001036609A1 Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
| 05/25/2001 | WO2001036608A1 Reversibly inactivated acidified plasmin |
| 05/25/2001 | WO2001036605A2 2786, a human aminopeptidase |
| 05/25/2001 | WO2001036604A2 Nucleic acids encoding endotheliases, endotheliases and uses thereof |
| 05/25/2001 | WO2001036489A2 Erythropoietin forms with improved properties |
| 05/25/2001 | WO2001036462A2 Protein c derivatives |
| 05/25/2001 | WO2001036454A1 Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
| 05/25/2001 | WO2001036450A1 S-allylmercaptoglutathione and uses thereof |
| 05/25/2001 | WO2001036440A1 23 human secreted proteins |